Hospital.Help

Paris A modeling study from France suggests that prevention campaigns with nirsevimab can effectively reduce hospitalizations due to RSV-related bronchiolitis in children under 24 months of age. The researchers are now presenting their results in The Lancet Child & Adolescent Health (2024; DOI: 10.1016/S2352-4642(24)00143-3). The respiratory syncytial virus (RSV) is one of the leading causes of…